The Effects of Estrone (Ogen) on Spinal Bone Density of Postmenopausal Women

Steven T. Harris, Harry K. Genant, David J. Baylink, John Christopher G. Gallagher, Sherry Katz Karp, Maureen A. Mcconnell, Elizabeth M. Green, Ralph W. Stoll

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

The effects of cyclical treatment with estrone sulfate (0.3, 0.625, or 1.25 mg), plus calcium carbonate, on spinal trabecular bone density were compared with placebo in 120 postmenopausal women in this 2-year, multicenter, doubleblind study. While the placebo and 0.3-mg treatment groups lost bone density (-3.6% and -5.1%), the 0.625- and 1.25-mg treatment groups experienced no significant change from baseline at 24 months (-0.8% and +0.7%). The 1.25-mg treatment group was significantly different from the placebo group at 12,18, and 24 months. Although the 0.625-mg treatment group was significantly different from the placebo group only at 18 months, the data suggest that 0.625 and 1.25 mg of estrone sulfate had different effects than placebo and 0.3 mg of estrone sulfate and, given with supplemental calcium, are effective doses for the prevention of spinal bone loss.

Original languageEnglish
Pages (from-to)1980-1984
Number of pages5
JournalArchives of Internal Medicine
Volume151
Issue number10
DOIs
StatePublished - 1991

Fingerprint

Estrone
Bone Density
Placebos
Therapeutics
Placebo Effect
Calcium Carbonate
Multicenter Studies
estropipate
Calcium
Bone and Bones
estrone sulfate

All Science Journal Classification (ASJC) codes

  • Internal Medicine

Cite this

Harris, S. T., Genant, H. K., Baylink, D. J., Gallagher, J. C. G., Karp, S. K., Mcconnell, M. A., ... Stoll, R. W. (1991). The Effects of Estrone (Ogen) on Spinal Bone Density of Postmenopausal Women. Archives of Internal Medicine, 151(10), 1980-1984. https://doi.org/10.1001/archinte.1991.00400100060010

The Effects of Estrone (Ogen) on Spinal Bone Density of Postmenopausal Women. / Harris, Steven T.; Genant, Harry K.; Baylink, David J.; Gallagher, John Christopher G.; Karp, Sherry Katz; Mcconnell, Maureen A.; Green, Elizabeth M.; Stoll, Ralph W.

In: Archives of Internal Medicine, Vol. 151, No. 10, 1991, p. 1980-1984.

Research output: Contribution to journalArticle

Harris, ST, Genant, HK, Baylink, DJ, Gallagher, JCG, Karp, SK, Mcconnell, MA, Green, EM & Stoll, RW 1991, 'The Effects of Estrone (Ogen) on Spinal Bone Density of Postmenopausal Women', Archives of Internal Medicine, vol. 151, no. 10, pp. 1980-1984. https://doi.org/10.1001/archinte.1991.00400100060010
Harris, Steven T. ; Genant, Harry K. ; Baylink, David J. ; Gallagher, John Christopher G. ; Karp, Sherry Katz ; Mcconnell, Maureen A. ; Green, Elizabeth M. ; Stoll, Ralph W. / The Effects of Estrone (Ogen) on Spinal Bone Density of Postmenopausal Women. In: Archives of Internal Medicine. 1991 ; Vol. 151, No. 10. pp. 1980-1984.
@article{3151703afac34243b4a3c28e78600a1d,
title = "The Effects of Estrone (Ogen) on Spinal Bone Density of Postmenopausal Women",
abstract = "The effects of cyclical treatment with estrone sulfate (0.3, 0.625, or 1.25 mg), plus calcium carbonate, on spinal trabecular bone density were compared with placebo in 120 postmenopausal women in this 2-year, multicenter, doubleblind study. While the placebo and 0.3-mg treatment groups lost bone density (-3.6{\%} and -5.1{\%}), the 0.625- and 1.25-mg treatment groups experienced no significant change from baseline at 24 months (-0.8{\%} and +0.7{\%}). The 1.25-mg treatment group was significantly different from the placebo group at 12,18, and 24 months. Although the 0.625-mg treatment group was significantly different from the placebo group only at 18 months, the data suggest that 0.625 and 1.25 mg of estrone sulfate had different effects than placebo and 0.3 mg of estrone sulfate and, given with supplemental calcium, are effective doses for the prevention of spinal bone loss.",
author = "Harris, {Steven T.} and Genant, {Harry K.} and Baylink, {David J.} and Gallagher, {John Christopher G.} and Karp, {Sherry Katz} and Mcconnell, {Maureen A.} and Green, {Elizabeth M.} and Stoll, {Ralph W.}",
year = "1991",
doi = "10.1001/archinte.1991.00400100060010",
language = "English",
volume = "151",
pages = "1980--1984",
journal = "JAMA Internal Medicine",
issn = "2168-6106",
publisher = "American Medical Association",
number = "10",

}

TY - JOUR

T1 - The Effects of Estrone (Ogen) on Spinal Bone Density of Postmenopausal Women

AU - Harris, Steven T.

AU - Genant, Harry K.

AU - Baylink, David J.

AU - Gallagher, John Christopher G.

AU - Karp, Sherry Katz

AU - Mcconnell, Maureen A.

AU - Green, Elizabeth M.

AU - Stoll, Ralph W.

PY - 1991

Y1 - 1991

N2 - The effects of cyclical treatment with estrone sulfate (0.3, 0.625, or 1.25 mg), plus calcium carbonate, on spinal trabecular bone density were compared with placebo in 120 postmenopausal women in this 2-year, multicenter, doubleblind study. While the placebo and 0.3-mg treatment groups lost bone density (-3.6% and -5.1%), the 0.625- and 1.25-mg treatment groups experienced no significant change from baseline at 24 months (-0.8% and +0.7%). The 1.25-mg treatment group was significantly different from the placebo group at 12,18, and 24 months. Although the 0.625-mg treatment group was significantly different from the placebo group only at 18 months, the data suggest that 0.625 and 1.25 mg of estrone sulfate had different effects than placebo and 0.3 mg of estrone sulfate and, given with supplemental calcium, are effective doses for the prevention of spinal bone loss.

AB - The effects of cyclical treatment with estrone sulfate (0.3, 0.625, or 1.25 mg), plus calcium carbonate, on spinal trabecular bone density were compared with placebo in 120 postmenopausal women in this 2-year, multicenter, doubleblind study. While the placebo and 0.3-mg treatment groups lost bone density (-3.6% and -5.1%), the 0.625- and 1.25-mg treatment groups experienced no significant change from baseline at 24 months (-0.8% and +0.7%). The 1.25-mg treatment group was significantly different from the placebo group at 12,18, and 24 months. Although the 0.625-mg treatment group was significantly different from the placebo group only at 18 months, the data suggest that 0.625 and 1.25 mg of estrone sulfate had different effects than placebo and 0.3 mg of estrone sulfate and, given with supplemental calcium, are effective doses for the prevention of spinal bone loss.

UR - http://www.scopus.com/inward/record.url?scp=0025954637&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025954637&partnerID=8YFLogxK

U2 - 10.1001/archinte.1991.00400100060010

DO - 10.1001/archinte.1991.00400100060010

M3 - Article

C2 - 1929686

AN - SCOPUS:0025954637

VL - 151

SP - 1980

EP - 1984

JO - JAMA Internal Medicine

JF - JAMA Internal Medicine

SN - 2168-6106

IS - 10

ER -